2016年sJIA-MAS标准与KD-MAS阶梯治疗:联合队列与文献综述
单中心回顾性队列研究纳入22例临床诊断的川崎病相关巨噬细胞活化综合征(KD-MAS)患者,比较三种诊断框架的符合比例。2016年sJIA-MAS标准符合比例最高(20/22),治疗多呈阶梯升级模式,HScore较高与治疗升级相关。
要点
- 2016年sJIA-MAS标准在KD-MAS中符合比例最高(20/22)。
- 治疗多从IVIG±糖皮质激素起始,必要时升级至免疫抑制剂/生物制剂。
- HScore较高(中位274 vs 199)与治疗升级相关。
核心结论
- 2016年sJIA-MAS标准在本队列KD-MAS中符合比例最高。
- 队列与文献病例的治疗普遍呈阶梯升级模式。
- 较高HScore与治疗升级同时出现,提示其反映基线严重度。
研究设计与样本
- 单中心回顾性队列研究,临床诊断KD-MAS共22例,总队列3786例。
- MAS分别按HLH-2004、HLH-2009或2016年sJIA-MAS标准分类。
- 采用Firth逻辑回归评估HScore与治疗升级的关联,并行文献综述。
主要发现
- KD-MAS发病率0.6%(22/3786),平均年龄3.72岁,冠状动脉受累77.2%。
- 符合各框架的比例:HLH-2004为14/22,HLH-2009为18/22,2016年sJIA-MAS为20/22,11例符合全部三种。
- 血细胞减少、肝功能障碍和凝血障碍常见。
- 强化治疗组HScore中位274,标准治疗组199(p=0.020)。
- HScore每增加10分,升级治疗几率更高(单变量OR 1.44;校正后OR 1.37)。
关键数值与推荐
- 2016年sJIA-MAS标准符合20/22例临床诊断KD-MAS。
- HLH-2004标准符合14/22例,HLH-2009标准符合18/22例。
- HScore中位强化治疗274 vs 标准治疗199(p=0.020)。
- HScore每增加10分与治疗升级相关(单变量OR 1.44;校正OR 1.37)。
临床怎么用
- 在KD-MAS诊断中可优先参考2016年sJIA-MAS标准。
- 治疗可按IVIG±糖皮质激素起始,必要时升级至免疫抑制剂/生物制剂。
- HScore有助于识别可能需要治疗升级的基线重症患者。
局限性
- 单中心回顾性设计,样本量有限(22例KD-MAS)。
- 文献部分为描述性综述,非系统检索。
- HScore与治疗升级的关联需前瞻性多中心研究验证增量价值与风险分层阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe diagnostic framework classification, treatment patterns and outcomes in Kawasaki disease-associated macrophage activation syndrome (KD-MAS) using a single-centre cohort and a structured descriptive synthesis of published cases to inform hypothesis generation and future refinement of diagnostic and management strategies for KD-MAS. METHODS: We performed a retrospective single-centre cohort study. MAS was classified by haemophagocytic lymphohistiocytosis (HLH)-2004, HLH-2009 or 2016 systemic juvenile idiopathic arthritis (sJIA)-MAS criteria. Data were abstracted around a prespecified MAS window; severity was indexed by haemophagocytic syndrome diagnostic score (HScore) and the association between HScore and treatment escalation was assessed using Firth's logistic regression. In parallel, we conducted a literature review. RESULTS: In our centre, incidence was 0.6% (22/3786); mean age was 3.72 years; coronary involvement was 77.2%. The proportions of clinician-diagnosed KD-MAS cases fulfilling each framework were HLH-2004 14/22, HLH-2009 18/22 and 2016 sJIA-MAS 20/22; 11 met all three. Cytopenias, liver dysfunction and coagulopathy were frequent; management followed stepwise escalation from intravenous immunoglobulin (IVIG) or corticosteroid monotherapy to IVIG plus corticosteroids and, when required, to adjunct immunosuppressive/biologic therapy; similar patterns appeared in the literature. HScore was higher with intensified therapy than with standard therapy (median 274 vs 199; p=0.020). Each 10-point HScore increase was associated with higher odds of escalation (OR 1.44 univariable; 1.37 adjusted). CONCLUSION: The 2016 sJIA-MAS criteria demonstrate the highest proportion fulfilling criteria in our cohort for KD-MAS. Treatment in our cohort and in published cases generally reflected a stepwise, typically progressing from IVIG±glucocorticoids to adjunct immunosuppressants/biologics. Higher HScores co-occurred with escalation, suggesting they capture baseline severity; prospective multicentre studies are needed to test incremental value and risk-stratification thresholds.
引用
- Zhao Y, Tang Z, Liu H, et al. 2016 sJIA-MAS criteria and a step-up therapeutic approach in KD-MAS: insights from a combined cohort and literature review. RMD Open. 2026. PMID: 41802834. doi:10.1136/rmdopen-2025-006524
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。